Methods Study design Representatives of the companies Bristol-Myers Squibb, Novo Nordisk, Sanofi, Merck, Novartis, Boehringer Ingelheim and Takeda were contacted with the request to provide the event numbers of acute pancreatitis with the respective drug and non-incretin comparators as well as the corresponding number of patient-years of exposure (PYOs) for the approved GLP-1 receptor agonists exenatide twice daily, exenatide weekly, liraglutide and lixisenatide, as well as the DPP-4 inhibitors sitagliptin, saxagliptin, vildagliptin, alogliptin and linagliptin
The REDF program is being architected to treat Retatrutide not merely as a reagent, but as a model system for interrogating multi-axis receptor pharmacology, with experimental workstreams spanning receptor-proximal endpoints, second-messenger cascades, and extended kinetic behaviors in appropriate non-clinical settings
Enter your current weight and timeline to see realistic expectations in the STEP 1 clinical trial (NEJM, 2021), patients on semaglutide lost an average of 14.9% of body weight over 68 weeks
This triple action on GIP, GLP-1, and glucagon receptors creates stronger appetite suppression and greater metabolic effects than single or dual agonist peptides
M.PachikianB
